India had been expecting a positive news from the World Health Organization (WHO) vis-à-vis the acceptance of its Covaxin vaccine for COVID-19.
A meeting of WHO’s Strategic Advisory Group of Experts (SAGE) was scheduled to take a call on Tuesday after a discussion on Phase 1-3 trial results of the Bharat Biotech-developed and manufactured vaccine.
But India has to wait as WHO tweeted that a meeting is scheduled for next week to assess the risk and benefits of Covaxin to decide on its emergency using authorisation.
“WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin,” WHO tweeted.
Also Read: WHO Further Delays Covaxin Clearance Over Technical Queries, Say Sources
The UN health agency stated that the assessment will be finalized next week if additional information submitted by Bharat Biotech addresses all questions raised by the experts.
According to WHO, Emergency Use Listing process determines if the vaccine is quality-assured, safe and effective, .
Bharat Biotech has been submitting data and additional information at WHO’s request.
